Slides were dried at room temperature overnight for imaging
Results Descriptive analysis During the study period, a total of 6,437,182 AE reports were obtained from the FAERS database after exclusion of duplicates, containing 11,326 semaglutide-related gastrointestinal AEs in 5,442 patients
This particular form can cross the blood-brain barrier, offering neuroprotective and cognitive benefits
The substance liraglutide, under the brand name Saxenda, was introduced to the market in 2015 as the first GLP-1 RA approved as a treatment complementary to exercise and diet for weight control in patients with high BMI (obese or overweight with weight-related comorbidities) [3]
Cardiovascular complications of modern multiple myeloma therapy: A pharmacovigilance study